GN Store Nord (OTCMKTS:GNNDY) vs. Oramed Pharmaceuticals (NASDAQ:ORMP) Financial Comparison

Oramed Pharmaceuticals (NASDAQ:ORMP) and GN Store Nord (OTCMKTS:GNNDY) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, earnings, risk, valuation and dividends.

Valuation & Earnings

This table compares Oramed Pharmaceuticals and GN Store Nord”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$1.34 million	96.83	-$19.06 million	$1.26	2.59
GN Store Nord	$2.54 billion	N/A	$98.86 million	$2.06	21.02

GN Store Nord has higher revenue and earnings than Oramed Pharmaceuticals. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than GN Store Nord, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 17.8% of Oramed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Oramed Pharmaceuticals and GN Store Nord’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.57%	-5.22%
GN Store Nord	3.97%	6.31%	2.29%

Analyst Ratings

This is a summary of current recommendations and price targets for Oramed Pharmaceuticals and GN Store Nord, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0	1	0	0	2.00
GN Store Nord	1	2	2	0	2.20

Risk and Volatility

Oramed Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, GN Store Nord has a beta of 1.94, meaning that its stock price is 94% more volatile than the S&P 500.

Summary

GN Store Nord beats Oramed Pharmaceuticals on 10 of the 12 factors compared between the two stocks.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

About GN Store Nord

GN Store Nord A/S provides hearing, audio, video, and gaming solutions in Denmark, rest of Europe, North America, and internationally. The company operates through GN Hearing and GN Audio segments. The GN Hearing segment produces and sells hearing instruments and products. The GN Audio segment supplies headsets, video cameras, and speakerphones for professional use and consumer products. It offers its products under the ReSound, Jabra, Beltone, Interton, Danavox, BlueParrott, FalCom, and SteelSeries brands. GN Store Nord A/S was founded in 1869 and is based in Ballerup, Denmark.